June 7, 2025

vivodyne-khosla-ventures-investment-drug-testing-penn

Investment

Vivodyne raised $40 million from Khosla Ventures and others

Vivodyne, a Penn spinout that creates human tissue to replace animal testing in drug development, has raised $40 million in a second round of venture capital investment. The company headquartered in Philadelphia’s Curtis building in Center City aims to speed up drug discovery and development, while eliminating the financial risk involved in testing treatments in

Read More
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline